Skip to content

Study · Systematic review · 2025

2 results

Effects of Semaglutide and Tirzepatide on Recurrent Weight Gain After Bariatric Surgery: A Systematic Review and Meta-analysis.

Osorio Manyari AA, Armas Alvarez AL, Osorio Manyari JD, Onieva Gonzalez F, Pouwels S

Obesity surgery28 Nov 2025Cited by 1 (Europe PMC)

PMID41313431 (opens in a new tab)DOI10.1007/s11695-025-08414-2 (opens in a new tab)PepBankPUB-41313431
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In patients with recurrent weight gain after bariatric surgery, pooled semaglutide data showed a percentage total weight loss of 10.97%.

    In plain wordsIn people who regained weight after weight-loss surgery, semaglutide was linked to about 10.97% total weight loss.

    Peptide
    Semaglutide
    Outcome
    DecreasePercentage total weight loss after bariatric surgery
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    %TWL
    −10.97%
    semaglutide

    Source sentences

    Summary
    The percentage total weight loss (%TWL) was - 10.97% [95% CI, - 13.41 to - 8.53; p < 0.05] for semaglutide and - 13.63% [95% CI, - 22.59 to - 4.67; p < 0.05] for tirzepatide.
    1 context sentence
    Summary · context
    Eight retrospective studies and 964 patients were included.
  2. 02HumanSystematic reviewEfficacy outcome

    In patients with recurrent weight gain after bariatric surgery, pooled tirzepatide data showed a percentage total weight loss of 13.63%.

    In plain wordsIn people who regained weight after weight-loss surgery, tirzepatide was linked to about 13.63% total weight loss.

    Peptide
    Tirzepatide
    Outcome
    DecreasePercentage total weight loss after bariatric surgery
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    %TWL
    −13.63%
    tirzepatide

    Source sentences

    Summary
    The percentage total weight loss (%TWL) was - 10.97% [95% CI, - 13.41 to - 8.53; p < 0.05] for semaglutide and - 13.63% [95% CI, - 22.59 to - 4.67; p < 0.05] for tirzepatide.
    1 context sentence
    Summary · context
    Eight retrospective studies and 964 patients were included.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:07 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.